ROXATIDINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H26N2O3
Molecular Weight	306.3999
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=BCCREUFCSIMJFS-UHFFFAOYSA-N

InChI=1S/C17H26N2O3/c20-14-17(21)18-8-5-11-22-16-7-4-6-15(12-16)13-19-9-2-1-3-10-19/h4,6-7,12,20H,1-3,5,8-11,13-14H2,(H,18,21)

HIDE SMILES / InChI

Molecular Formula	C17H26N2O3
Molecular Weight	306.3999
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H2 receptor 46	Antagonist 2,778
Estrogen receptor 75	Agonist 2,678

Conditions

Condition	Modality	Highest Phase	Product
Peptic ulcer 72	Primary	Approved 8,429	ROXATIDINE
Gastroesophageal reflux disease 59	Primary	Approved 8,429	ROXATIDINE
Gastritis 45	Primary	Approved 8,429	ROXATIDINE
Upper gastrointestinal haemorrhage 4	Primary	Approved 8,429	ROXATIDINE
Zollinger-Ellison syndrome 17	Primary	Approved 8,429	ROXATIDINE

C_max

Value	Dose	Analyte	Population
157.5 ng/mL	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
329 ng/mL	75 mg single, oral	ROXATIDINE plasma	Homo sapiens
628.5 ng/mL	150 mg single, oral	ROXATIDINE plasma	Homo sapiens
353.6 ng/mL	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
530.2 ng/mL	75 mg single, oral	ROXATIDINE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
1353.2 ng × h/mL	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
2424.5 ng × h/mL	75 mg single, oral	ROXATIDINE plasma	Homo sapiens
5275.2 ng × h/mL	150 mg single, oral	ROXATIDINE plasma	Homo sapiens
2053.6 ng × h/mL	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
3587.5 ng × h/mL	75 mg single, oral	ROXATIDINE plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
5.57 h	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
5.03 h	75 mg single, oral	ROXATIDINE plasma	Homo sapiens
5.01 h	150 mg single, oral	ROXATIDINE plasma	Homo sapiens
4.62 h	37.5 mg single, oral	ROXATIDINE plasma	Homo sapiens
4.17 h	75 mg single, oral	ROXATIDINE plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
85%			ROXATIDINE unknown	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
600 mg single, oral Highest studied dose	healthy, ADULT	Other AEs: Skin rash...
150 mg 1 times / day multiple, oral Recommended	unhealthy, ADULT	Disc. AE: Rash...

Showing 1 to 2 of 2 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Skin rash	10%	600 mg single, oral Highest studied dose	healthy, ADULT
Rash	grade 3, 0.5% Disc. AE	150 mg 1 times / day multiple, oral Recommended	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3,367	no

Showing 1 to 1 of 1 entries

Previous1Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.

Route of Administration: Other

In Vitro Use Guide

6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1

Substance Class	Chemical
Record UNII	IV9VHT3YUM
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

ROXATIDINE

Official Name

English

ROXIT

Brand Name

English

Roxatidine [WHO-DD]

Common Name

English

2-HYDROXY-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL)ACETAMIDE

Systematic Name

English

ROXATIDINE [VANDF]

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

H₂-receptor antagonists

WHO-ATC

A02BA06

H₂-receptor antagonists

WHO-VATC

QA02BA06

Anti-ulcer Agent

NCI_THESAURUS

C29702

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

RXCUI

114817

PRIMARY

RxNorm

ChEMBL

CHEMBL46102

PRIMARY

CAS

78273-80-0

PRIMARY

EPA CompTox

DTXSID30228937

PRIMARY

EVMPD

SUB10396MIG

PRIMARY

Showing 1 to 5 of 12 entries

Previous1 2 3Next

Show entries

Related Record

Type

Details


					XC55JSP2CX

HISTAMINE H2 RECEPTOR

TARGET -> INHIBITOR


					8MN79F61ZI

ROXATIDINE HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					ZUP3LSD0DO

ROXATIDINE ACETATE

PARENT -> METABOLITE ACTIVE

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					IV9VHT3YUM

ROXATIDINE

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as victim

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound